Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider's stock worth $112,000 after acquiring an additional 33 shares in the last quarter.
Want to see what other hedge funds are holding ZBH? Park Avenue Institutional Advisers LLC boosted its stake in shares of Zimmer Biomet Holdings by 1.2% in the first quarter. Over the last month, company shares are -0.91%. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider's stock valued at $139,000 after buying an additional 256 shares in the last quarter. Finally, FirstMerit Bank N A Trustee bought a new stake in shares of Zimmer Biomet Holdings during the second quarter worth about $247,000. Gabelli started coverage on shares of Zimmer Biomet Holdings in a report on Thursday, August 24th. (NASDAQ:UCTT) [Trend Analysis] share price swings at $24.35 with percentage change of -0.16% in Thursday trading session. These holdings make up 90.45% of the company's outstanding shares.
COPYRIGHT VIOLATION NOTICE: "Zimmer Biomet Holdings, Inc". The company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $1.97 by $0.05. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Currently Zimmer Biomet Holdings, Inc. For the quarter ending Mar-18, 13 analysts have a mean sales target of 2,029.44 million whilst for the year ending Dec-17, 27 analysts have a mean target of 7,831.62 million. During the same period in the previous year, the firm earned $1.79 EPS. Analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.97 earnings per share for the current year.
Zimmer Biomet Holdings, Inc. also announced a dividend which was paid on Friday October 27th, 2017. Investors of record on Friday, September 22nd were issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 21st. The dividend was $0.240 per share for the quarter or $0.96 on an annualized basis. Zimmer Biomet Holdings's dividend payout ratio is now 27.59%. Piper Jaffray Companies lowered shares of Zimmer Biomet Holdings from an "overweight" rating to a "neutral" rating in a report on Thursday. BidaskClub lowered Zimmer Biomet Holdings from a "hold" rating to a "sell" rating in a research note on Tuesday, August 1st. July 28 investment analysts at Leerink Swann left the company rating at "Outperform" but raised the price target from $135.00 to $146.00. Finally, Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the stock a "buy" rating in a research report on Friday, July 28th. Out of 3 Wall Street analysts rating Knight Transportation, 0 give it "Buy", 0 "Sell" rating, while 3 recommend "Hold". They issued a "buy" rating and a $142.00 price target for the company.
In other news, insider David A. Jr. The stock's average target of $30.50 is -25.72% below today's ($41.06) share price. Stock price crosses of key moving averages may be used to help identify certain entry or exit points, and possible shifts in the current trend. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
About 1.46M shares traded or 2.10% up from the average. (ZBH)'s shares. The total value of these holdings, in millions, is $21,444.
Investors are always on the look for the next great stock to own. The disclosure for this sale can be found here. As the profitability measures are important to company managers and owners alike.
Zimmer Biomet Holdings, Inc.is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.